Ardelyx (ARDX) Shareholder's Equity Growth (1y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.02% |
| Dec 31, 2025 | -3.66% |
| Sep 30, 2025 | -2.54% |
| Jun 30, 2025 | -5.07% |
| Mar 31, 2025 | -3.46% |
| Dec 31, 2024 | 3.88% |
| Sep 30, 2024 | -17.19% |
| Jun 30, 2024 | 19.35% |
| Mar 31, 2024 | 20.31% |
| Dec 31, 2023 | 69.65% |
| Sep 30, 2023 | 185.91% |
| Jun 30, 2023 | 132.20% |
| Mar 31, 2023 | 95.39% |
| Dec 31, 2022 | 19.02% |
| Sep 30, 2022 | -17.89% |
| Jun 30, 2022 | -54.88% |
| Mar 31, 2022 | -50.93% |
| Dec 31, 2021 | -34.49% |
| Sep 30, 2021 | -38.00% |
| Jun 30, 2021 | -19.67% |
| Mar 31, 2021 | -22.02% |
| Dec 31, 2020 | -32.44% |
| Sep 30, 2020 | 167.18% |
| Jun 30, 2020 | 113.29% |
| Mar 31, 2020 | 82.66% |
| Dec 31, 2019 | 61.17% |
| Sep 30, 2019 | -65.25% |
| Jun 30, 2019 | -58.01% |
| Mar 31, 2019 | -28.79% |
| Dec 31, 2018 | -16.87% |
| Sep 30, 2018 | 11.70% |
| Jun 30, 2018 | 12.72% |
| Mar 31, 2018 | -23.08% |
| Dec 31, 2017 | -27.87% |
| Sep 30, 2017 | -43.18% |
| Jun 30, 2017 | 3.11% |
| Mar 31, 2017 | -0.04% |
| Dec 31, 2016 | 77.36% |
| Sep 30, 2016 | 78.13% |
| Jun 30, 2016 | -1.16% |
| Mar 31, 2016 | 189.22% |
| Dec 31, 2015 | 79.46% |
| Sep 30, 2015 | 97.67% |
| Jun 30, 2015 | 126.29% |
| Dec 31, 2014 | 195.59% |